S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Capnia Inc shares have surged to a 52-week high, reaching a price level of $74.11, as investors rally behind the company’s robust performance and future prospects. With a market capitalization of $3.37 billion, the company’s stock currently trades above its InvestingPro Fair Value, suggesting premium pricing. Analyst price targets range from $81 to $123, indicating potential further upside. This milestone reflects a significant uptrend in the company’s stock value, marking an impressive 1-year change of 87.82%. The surge to a 52-week high underscores the market’s confidence in Capnia, as it continues to outperform expectations and attract investor interest. InvestingPro analysis reveals strong liquidity with a current ratio of 15.68 and a negative beta of -2.29, suggesting the stock often moves counter to market trends. Discover 11 more exclusive ProTips and comprehensive research reports available on InvestingPro.
In other recent news, Soleno Therapeutics (NASDAQ:SLNO) has launched VYKAT XR, an FDA-approved treatment for hyperphagia in individuals with Prader-Willi syndrome (PWS). This development follows the FDA’s approval of the drug on March 26, 2025, making it the first treatment specifically approved for this condition. Piper Sandler has maintained an Overweight rating on Soleno’s stock, reflecting optimism about the drug’s market potential. Similarly, H.C. Wainwright increased its price target for Soleno to $100, citing the FDA approval as a significant milestone. Stifel also raised its price target to $108, highlighting the "blockbuster opportunity" presented by the drug’s approval.
In another recent development, Soleno Therapeutics appointed CBIZ (NYSE:CBZ) CPAs as its new auditor after Marcum LLP resigned. The change was made effective for the fiscal year ending December 31, 2025, following CBIZ’s acquisition of certain business segments of Marcum. During Marcum’s tenure, they did not issue any adverse opinions on Soleno’s financial statements, although they noted a material weakness in internal controls as of December 31, 2024. Soleno’s recent activities, including the commercial launch of VYKAT XR and the auditor transition, reflect significant developments in the company’s strategic and operational landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.